Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study

Date
2021
Author
Chung, Byung Ha
Pereira de Santana Gomes, Andrea J.
Lopez-Gitlitz, Angela
Miladinovic, Branko
Basch, Ethan
Given, Robert
Ye, Dingwei
Uemura, Hirotsugu
Merseburger, Axel S.
Juarez Soto, Alvaro
ÖZGÜROĞLU, Mustafa
Chi, Kim N.
Agarwal, Neeraj
McQuarrie, Kelly
Bjartell, Anders
Chowdhury, Simon
Metadata
Show full item record
Abstract
Purpose: We performed an exploratory analysis of prostate cancer-related pain and fatigue on health-related quality of life in patients with metastatic castration-sensitive prostate cancer receiving apalutamide (240 mg/day) or placebo, with continuous androgen deprivation therapy (ADT), in the phase 3, randomized, double-blind, placebo controlled TITAN trial (NCT02489318).
URI
http://hdl.handle.net/20.500.12627/168911
https://doi.org/10.1097/ju.0000000000001841
Collections